platinum has been researched along with Prostatic Neoplasms, Castration-Resistant in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 5 (71.43) | 2.80 |
| Authors | Studies |
|---|---|
| Aytes, A; Font, A; Ruiz de Porras, V | 1 |
| Fujimoto, N; Fujisawa, M; Harada, K; Harada, M; Kimuro, R; Minato, A; Nagata, Y; Shiota, M; Tomisaki, I | 1 |
| Donix, L; Dubrovska, A; Erb, HHH; Erdmann, K; Fuessel, S; Peitzsch, C; Pfeifer, M; Thomas, C | 1 |
| Badia, J; Balcells, C; Baldomà, L; Cascante, M; Crespo, M; Font-Bardia, M; Lázaro, A; Quirante, J; Rissanen, K; Rodríguez, L; Ward, JS | 1 |
| Aytes, A; Bakht, M; Beltran, H; Buisan, O; Bystrup, S; Castro, E; Conteduca, V; Font, A; Indacochea, A; Jimenez, N; Marin-Aguilera, M; Martinez-Balibrea, E; Mellado, B; Olmos, D; Palomero, L; Pardo, JC; Piulats, JM; Ruiz de Porras, V; Solé-Blanch, C; Suarez, JF; Wang, XC | 1 |
| Aronson, W; Freedland, S | 1 |
| Armstrong, AJ; George, D; Gupta, RT; Harrison, M; Healy, P; Humeniuk, MS; McNamara, M; Ramalingam, S; Wu, Y; Zhang, T | 1 |
2 review(s) available for platinum and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; DNA Repair; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Platinum; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2021 |
Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Humans; Male; Mutation; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms, Castration-Resistant; Recombinational DNA Repair; Treatment Outcome | 2021 |
5 other study(ies) available for platinum and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
Acquired resistance to irradiation or docetaxel is not associated with cross-resistance to cisplatin in prostate cancer cell lines.
Topics: Cell Line; Cisplatin; Docetaxel; Humans; Male; Platinum; Prostatic Neoplasms, Castration-Resistant | 2022 |
Luminescent Pt
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cisplatin; Colorectal Neoplasms; Coordination Complexes; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Male; Molecular Conformation; Platinum; Prostatic Neoplasms, Castration-Resistant; Spectrometry, Fluorescence | 2020 |
Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Docetaxel; Humans; Male; Mice; Platinum; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-bcl-2; Taxoids | 2021 |
Commentary on "Biallelic inactivation of BRCA2 in platinum-sensitive metastatic castration-resistant prostate cancer". Cheng HH, Pritchard CC, Boyd T, Nelson PS, Montgomery B. Eur Urol. Jun 2016;69(6):992-5.
Topics: BRCA2 Protein; DNA Repair; Germ-Line Mutation; Humans; Male; Orchiectomy; Platinum; Prostatic Neoplasms, Castration-Resistant | 2017 |
Platinum sensitivity in metastatic prostate cancer: does histology matter?
Topics: Adenocarcinoma; Aged; Disease Progression; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neuroendocrine Tumors; Platinum; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2018 |